4DMedical Ltd's stock soared 8.32% intraday on Friday following a significant regulatory milestone for the company's flagship technology.
The surge comes after the company announced it received Therapeutic Goods Administration (TGA) approval and inclusion on the Australian Register of Therapeutic Goods for its non-contrast ventilation-perfusion imaging software, CT:VQ. This approval enables the commercial use of the technology across Australia.
CT:VQ derives regional lung function information from standard CT scans without the need for injections or contrast agents. The company stated it will now seek Medicare reimbursement through the Medical Services Advisory Committee, which could facilitate broader adoption in healthcare settings.